Marginal Zone Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Suspended
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
I
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Recruiting
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Concord, California
  • +153 more
2022-04-06
Apr 6, 2022
U
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Recruiting
  • Non-Hodgkin Lymphoma
  • +7 more
  • Mosunetuzumab
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-28
Mar 28, 2022
B
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
2022-03-14
Mar 14, 2022
C
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
Recruiting
  • Marginal Zone Lymphoma
  • Wien, Austria
  • +19 more
2022-03-14
Mar 14, 2022
Q
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
2022-03-11
Mar 11, 2022
I
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
2022-03-24
Mar 24, 2022
U
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Not yet recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • (no location specified)
2022-03-15
Mar 15, 2022
C
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
2022-03-09
Mar 9, 2022
C
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Active, not recruiting
  • Adult Immunoblastic Lymphoma
  • +12 more
  • Cytology Specimen Collection Procedure
  • Birmingham, Alabama
  • +129 more
2022-03-23
Mar 23, 2022
U
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
2022-03-08
Mar 8, 2022
T
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
2022-03-22
Mar 22, 2022
B
A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies
Recruiting
  • B-cell Malignancy
  • +4 more
  • Louisville, Kentucky
  • +4 more
2022-03-22
Mar 22, 2022
T
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
2022-03-22
Mar 22, 2022
F
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Recruiting
  • Acute Biphenotypic Leukemia
  • +18 more
  • Aurora, Colorado
  • +2 more
2022-03-02
Mar 2, 2022
J
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Not yet recruiting
  • B-Cell Lymphoma
  • +8 more
  • Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
  • Pittsburgh, Pennsylvania
    AHN Cancer Institute - West Penn Hospital
2022-03-08
Mar 8, 2022
C
Obinutuzumab in Marginal Zone Lymphoma
Recruiting
  • Marginal Zone Lymphoma
  • Bochum, Germany
  • +15 more
2022-03-14
Mar 14, 2022
A
A Study of Nemtabrutinib (MK-1026) (ARQ 531) in Participants With Selected Hematologic Malignancies
Active, not recruiting
  • Lymphoma, B-Cell
  • +8 more
  • Scottsdale, Arizona
  • +9 more
2022-03-10
Mar 10, 2022
M
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Tucson, Arizona
  • +97 more
2022-03-10
Mar 10, 2022
M
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Recruiting
  • Marginal Zone Lymphoma
  • Duarte, California
  • +7 more
2022-03-09
Mar 9, 2022
M
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Recruiting
  • Marginal Zone Lymphoma
  • Los Angeles, California
  • +12 more
2022-03-09
Mar 9, 2022
B
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
2022-03-08
Mar 8, 2022
M
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Zandelisib (ME-401)
  • Tucson, Arizona
  • +115 more
2022-03-08
Mar 8, 2022
U
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
Recruiting
  • Marginal Zone Lymphoma
  • Graz, Austria
  • +10 more
2022-03-07
Mar 7, 2022
J
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Active, not recruiting
  • Follicular Lymphoma
  • +3 more
  • Vitamin D
  • +2 more
  • Miami, Florida
  • +6 more
2022-03-06
Mar 6, 2022